Edition:
India

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

40.91USD
2:29am IST
Change (% chg)

$-0.89 (-2.13%)
Prev Close
$41.80
Open
$41.50
Day's High
$41.85
Day's Low
$40.55
Volume
39,744
Avg. Vol
21,772
52-wk High
$44.38
52-wk Low
$13.01

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $381.96
Shares Outstanding(Mil.): 13.01
Dividend: --
Yield (%): --

Financials

BRIEF-Urogen Pharma Q3 loss per share $0.02

* Urogen Pharma reports third quarter 2017 financial results and recent corporate developments

14 Nov 2017

BRIEF-Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​

* Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​ Source: (http://bit.ly/2hdmj4k) Further company coverage:

08 Nov 2017

BRIEF-Urogen Pharma receives FDA fast track designation for Mitogel

* Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC)

29 Aug 2017

BRIEF-UroGen Pharma Q2 loss per share $0.70

* UroGen Pharma reports second quarter 2017 financial results and recent corporate developments

15 Aug 2017

BRIEF-Jay Moorin reports a 11.5 pct passive stake in Urogen Pharma

* Jay Moorin reports a 11.5 percent passive stake in Urogen Pharma Ltd as of May 9, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2ufDxWd) Further company coverage:

21 Jul 2017

BRIEF-Allergan submits investigational NDA for rtgel in combination with botox

* Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan

19 Jul 2017

BRIEF-Arkin Communications reports 13.32 pct stake in Urogen Pharma Ltd as on May 4, 2017

* Arkin Communications Ltd reports a 13.32 percent stake in Urogen Pharma Ltd as on May 4, 2017 - sec filing Source text (http://bit.ly/2qxuprm) Further company coverage:

30 May 2017

Earnings vs. Estimates